Royalty Pharma
RPRX
213 hedge funds and large institutions have $10.8B invested in Royalty Pharma in 2021 Q1 according to their latest regulatory filings, with 49 funds opening new positions, 85 increasing their positions, 56 reducing their positions, and 34 closing their positions.
52% more repeat investments, than reductions
Existing positions increased: 85 | Existing positions reduced: 56
44% more first-time investments, than exits
New positions opened: 49 | Existing positions closed: 34
10% more funds holding in top 10
Funds holding in top 10: 10 → 11 (+1)
8% more funds holding
Funds holding: 198 → 213 (+15)
4.44% more ownership
Funds ownership: 59.3% → 63.74% (+4.4%)
2% more call options, than puts
Call options by funds: $46.5M | Put options by funds: $45.7M
5% less capital invested
Capital invested by funds: $11.4B → $10.8B (-$608M)
Top Buyers
| 1 |
Morgan Stanley
New York
|
+$1.15B |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$980M |
| 3 |
BlackRock
New York
|
+$219M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
+$143M |
| 5 |
State Street
Boston,
Massachusetts
|
+$110M |
Top Sellers
RPRX Hedge Fund Activity: Q1 2021 in Review
213 of the 5,695 institutional investors tracked by Wall St. Rank reported a position in Royalty Pharma (RPRX) for Q1 2021, worth a combined $10.8B — down 5.4% from $11.4B a quarter earlier.
Buyers outnumbered sellers: 49 funds opened new RPRX positions and 34 closed out — a net gain of 15 holders — while 85 added to existing stakes and 56 trimmed.
The largest buyer was Morgan Stanley, adding an estimated $1.15B. The largest seller was Adage Capital Partners, cutting an estimated $665M.
- 213 institutional investors held Royalty Pharma (RPRX) as of Q1 2021, up from 198 in Q4 2020.
- Funds reported $10.8B of Royalty Pharma stock for Q1 2021, down 5.4% quarter-over-quarter.
- 49 funds opened new Royalty Pharma positions in Q1 2021 and 34 closed out, a net change of +15 holders.
- The largest Royalty Pharma buyer in Q1 2021 was Morgan Stanley, an estimated $1.15B added.
- The largest Royalty Pharma seller in Q1 2021 was Adage Capital Partners, an estimated $665M sold.
Based on aggregated 13F filings for Q1 2021.